When the Tissue Changes: What Are We Actually Treating?

Lymphoedema, fibrosis, inflammation — and why “hard swelling” doesn’t tell us enough

Sometimes an image makes me stop.

Not necessarily because I agree with every word on it, but because it makes me think.

I recently came across an illustration describing the development of fibrosis in lymphoedema. The basic idea was familiar:

lymphatic impairment → protein-rich swelling → inflammation → fibrosis → further lymphatic impairment.

But I found myself looking at it and thinking:

Is that really the best way to explain what is happening?

Because we often hear lymphoedema described as an accumulation of protein-rich fluid.

And somewhere along the line that can turn into a much simpler story:

Protein sits there → the swelling gets hard → fibrosis develops.

Except that isn’t really what the biology tells us.

Protein doesn’t simply sit in the tissues until it somehow “turns into” fibrosis.

Something considerably more interesting is happening.

And strangely, some of this felt familiar.

An old teacher came back into my head

Around 2008 I did my original scar and connective-tissue training with South African physiotherapist Willem Fourie.

He was a big influence on the way I subsequently worked.

Long before I understood half of what I now understand about lymphatics, he encouraged us to think beyond the scar we could see.

What had happened underneath it?

What tissues had been disrupted?

What was gliding — and what wasn’t?

What had happened elsewhere because the body had adapted around that restriction?

And what was actually happening biologically as tissue healed and remodelled?

Fourie was particularly interested in people experiencing problems following breast-cancer surgery and radiotherapy. His 2008 paper examined women with upper-limb dysfunction following treatment for primary breast cancer and identified restrictive tissue gliding not simply at the surgical scar but through the axilla, lateral chest wall, upper arm and posterior shoulder region. His argument was that wider connective-tissue involvement could contribute to dysfunction after treatment.

That idea stayed with me.

Don’t just look where the scar is. Look at what happened to the system around it.

Fourie later described fibrosis rather beautifully as:

“a pathologic excess of normal tissue repair.”

And he was talking about TGF-β1.

In his chapter Surgery and Scarring, Fourie described excessive or sustained production of TGF-β1 as an important molecular mediator of fibrosis, stimulating cells towards increased extracellular-matrix deposition. He also emphasised that scar maturation is influenced by both the internal biological environment — including inflammatory mediators and growth factors — and the external mechanical environment.

I remember encountering these ideas during my training with him all those years ago.

Nearly twenty years later, I find myself reading contemporary lymphoedema research discussing TGF-β signalling (for a deeper dive read: I was taught not to fight the scar), fibroblasts, extracellular matrix, collagen deposition and chronic inflammation.

And thinking:

Hello again.

This isn’t evidence that everything we believed or did twenty years ago was correct.

Research moves on. So should practitioners.

But it does remind me how influential Fourie’s central question was on my own practice:

What has happened to the tissue — and why?

First: lymphoedema isn’t only a plumbing problem

We understandably talk about lymphoedema in terms of drainage.

Lymphatic transport becomes inadequate.

Fluid accumulates.

So we try to improve fluid management.

That makes sense.

But chronic lymphoedema is not simply a bucket containing too much fluid.

Research increasingly describes a much more complex biological process involving lymphatic stasis, chronic immune and inflammatory activity, adipose-tissue changes, extracellular-matrix remodelling and fibrosis.

And those processes interact.

That distinction matters.

Because eventually we may no longer be dealing with:

“Too much fluid in otherwise normal tissue.”

We may be dealing with:

tissue that has changed.

Welcome to the interstitium

Between our cells, vessels, fascia and other structures lies the interstitial space.

It isn’t empty.

It is a dynamic environment containing fluid, proteins and other macromolecules, extracellular matrix, cells and signalling molecules.

Normally there is continual exchange and clearance occurring within this environment, with the lymphatic system playing an essential role.

When lymphatic transport becomes chronically impaired, that environment changes.

And that’s where the fibrosis story becomes considerably more interesting.

Protein matters — but protein isn’t becoming fibrosis

Let’s clear this one up.

Protein-rich interstitial fluid is important in lymphoedema.

But protein itself doesn’t somehow solidify into fibrotic tissue.

Persistent lymphatic dysfunction can instead create an environment associated with chronic inflammatory and immune signalling.

Those signals influence the cells living within that tissue.

Fibroblasts — cells involved in maintaining and producing extracellular matrix — are among them.

And TGF-β is one of the important characters in this story.

The broader fibrosis literature has long identified TGF-β as an important profibrotic signalling pathway capable of activating fibroblasts and promoting extracellular-matrix production.

Human tissue research in breast-cancer-related lymphoedema has subsequently demonstrated increased collagen, fibronectin, fibroblast markers and TGF-β-associated pathological changes.

So the better story isn’t:

PROTEIN → FIBROSIS

It is something more like:

LYMPHATIC IMPAIRMENT

↓

ALTERED INTERSTITIAL ENVIRONMENT

fluid • proteins • macromolecules • immune activity

↓

PERSISTENT INFLAMMATORY / CELLULAR SIGNALLING

↓

FIBROBLAST ACTIVITY + EXTRACELLULAR-MATRIX REMODELLING

↓

COLLAGEN / FIBROADIPOSE CHANGE

↓

FIBROSIS + REDUCED TISSUE COMPLIANCE

↓

FURTHER CHALLENGE TO LYMPHATIC FUNCTION

That is not stagnant water becoming hard. That is biology changing tissue.

And then there’s fat

This part is frequently missing from simple explanations of lymphoedema.

Longstanding lymphatic dysfunction can involve adipose as well as fibrotic change.

Human tissue research has identified adipocyte enlargement and collagen deposition within lymphoedematous tissue.

Which raises an important clinical point.

If a longstanding enlarged limb contains varying proportions of:

fluid + adipose tissue + connective-tissue remodelling + fibrosis

why would we expect moving fluid alone to return that tissue to “normal”?

We shouldn’t.

And perhaps we need to be careful about the promises we make to people when we treat them.

“But it felt softer afterwards…”

Now we’re getting into territory that challenges me too.

Because I use my hands.

I assess tissue.

I notice changes in texture, movement and compliance before and after treatment.

And sometimes something genuinely does feel softer.

But I need to be careful about the biological story I attach to that observation.

Did I:

break down fibrosis?

Or did I change fluid distribution?

Reduce tissue pressure?

Improve superficial tissue glide?

 

Change muscle tone?

Improve movement?

Alter the way the tissue loads under my hand?

Create a temporary mechanical change?

Or influence several things simultaneously?

Those aren’t interchangeable.

My hands can tell me something changed.

They cannot necessarily tell me what changed at cellular level.

That is uncomfortable.

It’s also important.

Is fibrosis permanent?

We can talk about fibrosis as though tissue crosses an invisible line:

NOT FIBROTIC → FIBROTIC → PERMANENT

Biology isn’t necessarily that tidy.

Different people will have different degrees of fluid accumulation, inflammation, adipose deposition and fibrotic remodelling.

A firm limb isn’t necessarily one homogeneous block of irreversible scar tissue.

That does not give us permission to claim we’re “breaking fibrosis down.”

Instead it should make us more interested in measuring what changes.

Has volume changed?

Has tissue mobility changed?

Is movement easier?

Does the garment fit differently?

Has function improved?

Does the person report less heaviness?

And crucially:

Can they maintain that change when they leave my treatment room?

The skin isn’t wrapping paper

When we encounter fibrotic tissue, it’s tempting to think:

What technique can I use on this?

More pressure?

A tissue technique?

Negative pressure?

Tape?

But before any of those:

LOOK AT THE SKIN.

Lymphoedema carries an important cellulitis risk.

Skin may also be fragile, dry, inflamed, scarred, previously irradiated, healing or have altered sensation.

So before deciding that firm tissue needs more mechanical input, I want to know:

What does the skin look like?

Is it intact?

Is it fragile?

Has it been irradiated?

Is sensation normal?

Has there been cellulitis?

Is there inflammation?

Could my attempt to change the tissue create a bigger problem than the firmness I’m trying to treat?

Tape may sometimes be appropriate.

So may selected tissue techniques.

But:

“FIBROSIS PRESENT” ISN’T A TREATMENT PRESCRIPTION.

The skin gets a vote.

Actually, I think the skin gets the final vote.

 

So what tools do we actually have?

This is where I don’t want to replace one simplistic idea with another.

Not:

Fibrosis? Massage it.

And not:

Fibrosis? Here’s my toolbox.

Instead:

What am I trying to change?

Compression may be important for managing oedema and maintaining reductions.

Movement and exercise contribute muscle activity, joint movement, changing tissue pressures, strength and function.

Skin care protects a barrier we really cannot afford to ignore.

MLD may form part of lymphoedema management — but the evidence for the additional volume-reducing effect of MLD over other components of decongestive treatment is mixed.

That challenges me because MLD is one of my tools.

Good.

Training in a technique shouldn’t make me less willing to question it.

It should make me more responsible for understanding what it can and cannot reasonably claim to do.

The same applies to my hands-on scar and tissue work.

The same applies to compression.

The same applies to tape.

The same applies to exercise.

The tool doesn’t get to decide what happened simply because I know how to use it.

Perhaps “hard” isn’t a diagnosis

Two tissues can feel firm under my hands without being firm for the same reason.

There may be:

fluid

fibrosis

adipose change

scar

inflammation

skin change

muscle

venous involvement

radiotherapy-related change

or — probably quite often —

a combination.

So:

“It’s hard” isn’t the end of my assessment.

It’s the beginning of another question.

Why?

And suddenly I’m back with something Willem Fourie taught me all those years ago.

Don’t simply treat the bit you can see — or feel.

Understand the relationships around it.

Fourie’s 2008 breast-cancer study demonstrated restrictive tissue patterns extending beyond the obvious surgical scar. Four years later he was presenting “The Role of the Fascia in the Treatment of Lymphedema” at the 38th European Congress of Lymphology.

He was also teaching therapists to consider how connective-tissue pathology and dysfunction could develop following surgery, radiotherapy and other insults — and to use assessment to guide an individual treatment strategy rather than simply applying a technique.

I don’t think that way of thinking has always received the recognition it deserves.

It certainly influenced mine.

The cycle matters because it changes my question

The simple story is:

Lymphatics aren’t working → fluid accumulates → drain the fluid.

The biological story is considerably messier.

Lymphatic dysfunction.

Interstitial change.

Immune and inflammatory signalling.

Fibroblast activity.

Extracellular-matrix remodelling.

Fibrosis.

Adipose change.

Skin change.

Movement and function.

And all of it happening to one person, not in separate textbook chapters.

Which means perhaps my most useful question isn’t:

“Which technique treats fibrosis?”

It is:

“What am I actually trying to change?”

FI CLINICAL PEARL

YOUR HANDS FOUND SOMETHING.

THEY HAVEN’T TOLD YOU WHY YET.

FLUID?

INFLAMMATION?

FIBROSIS?

SCAR?

SKIN?

ADIPOSE CHANGE?

MUSCLE?

VENOUS INVOLVEMENT?

OR A COMBINATION?

ASSESS → CHOOSE → TREAT → MOVE → REASSESS

And perhaps, nearly twenty years after I first encountered some of these ideas in a room with Willem Fourie, I’ve ended up back at something remarkably simple:

Don’t start with the technique.

Start with the tissue.

Then remember there’s a person attached to it.

Nothing works in isolation. Everything works in combination.™

 

References & further reading

Fourie WJ (2008). Considering wider myofascial involvement as a possible contributor to upper extremity dysfunction following treatment for primary breast cancer. Journal of Bodywork and Movement Therapies, 12(4), 349–355. Fourie identified combinations of restrictive tissue gliding extending beyond the surgical scar in women experiencing upper-limb dysfunction following breast-cancer treatment.

Fourie WJ (2012). Surgery and Scarring. In: Schleip R, Findley TW, Chaitow L, Huijing PA (eds), Fascia: The Tensional Network of the Human Body. Churchill Livingstone/Elsevier, pp. 411–419. Particularly relevant to fibrosis, TGF-β1, ECM deposition, scar maturation and the relationship between tissue repair and function.

Fourie WJ (2012). The Role of the Fascia in the Treatment of Lymphedema. Presented at the 38th European Congress of Lymphology, physical-treatment session.

Wynn TA (2008). Cellular and molecular mechanisms of fibrosis. Journal of Pathology. An important overview of inflammatory and profibrotic signalling, including TGF-β, fibroblast/myofibroblast activity and excessive extracellular-matrix accumulation.

Plus the contemporary lymphoedema literature discussed throughout this article: human biopsy research examining TGF-β-associated fibrosis, collagen and extracellular-matrix changes; research into adipose remodelling; current lymphoedema consensus guidance; and systematic reviews of exercise, MLD and complete decongestive treatment.